loxiglumide

01/01/1999 - "In addition, the administration of loxiglumide improved both the biochemical and pathological changes of edematous acute pancreatitis induced by a closed duodenal loop in rats. "
03/01/2006 - "CCK antagonist loxiglumide is expected as an excellent clinical applicable agent for acute pancreatitis. "
01/01/2003 - "They also suggest that CCK is involved in basal pancreatic exocrine in conscious rats and that loxiglumide may be useful as a therapeutic agent for pancreatitis, even during fasting, by attenuating the basal pancreatic exocrine burden on the pancreas."
05/01/2002 - "By February 2000, loxiglumide had also been filed for approval in Japan for the treatment of acute pancreatitis by Mitsubishi-Tokyo [365460], [371091] and was still awaiting approval in October 2001 [422712], [430428]. "
01/01/1999 - "The effects of loxiglumide on hemorrhagic and necrotizing acute pancreatitis is controversial. "

04/01/1997 - "In conclusion, sure efficacy of loxiglumide in advanced pancreatic cancer was not demonstrated by our results. "
05/01/1993 - "It is suggested that loxiglumide inhibits the in vivo and in vitro growth of human pancreatic cancer, perhaps independently of its action as a CCK antagonist, and this study also suggests that loxiglumide may be a new type of therapeutic agent to be used for the treatment of human pancreatic cancer."
08/01/1992 - "[Effects of UFT and loxiglumide (CR1505) on liver metastasis of human pancreatic cancer cell line, KP-1 N in nude mice]."
01/01/1992 - "[Effect of combined use of CR 1505 with UFT on tumor growth of transplanted pancreatic cancer in the Syrian golden hamster: preliminary report]."
12/15/1993 - "The study was designed to evaluate the effects of the cholecystokinin antagonist loxiglumide (CR1505) on the growth of human pancreatic cancer. "

05/01/2002 - "Loxiglumide is awaiting approval in Japan where it is being developed for acute and chronic pancreatitis by Mitsubishi Pharma and Kaken Pharmaceuticals, respectively [365460], [449509]. "
07/01/2002 - "These results indicate that oral administration of loxiglumide may be useful in the treatment of patients with acute, painful attacks of chronic pancreatitis, and 600 mg/d is recommended as a beneficial dosage."
05/01/2002 - "In December 2001, analysts at Merrill Lynch predicted launch of loxiglumide in early 2002 for acute pancreatitis and late 2004 for chronic pancreatitis, with sales of Yen 1 billion in 2003 rising to Yen 6 billion in 2006 [450719]."
07/01/2002 - "The therapeutic efficacy of a CCK-A receptor antagonist, loxiglumide, in patients with painful acute attacks of chronic pancreatitis was evaluated. "
07/01/2002 - "Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan."

07/15/1989 - "Treatment of biliary colic with loxiglumide."
08/01/2003 - "Loxiglumide is highly effective in obtaining pain relief in patients with biliary colic. "
08/01/2003 - "Fourteen patients with biliary colic but no suspicion for acute cholecystitis, were randomly and blindly assigned to loxiglumide (50 mg i.v.) or hyoscine-N-butyl bromide (20 mg i.v.) treatment. "

01/01/1995 - "GB volumes during postprandial refilling were significantly greater during loxiglumide than placebo infusion (P < 0.01), but they did not differ between gallstone and control subjects. "